To place on the market (or not)?
This article was originally published in RAJ Devices
The definition of the term "placing on the market" is critical for medical device manufacturers whose products are marketed in the EU. It is in fact one of the core issues relating to the three EU medical device directives (the Medical Devices Directive – 93/42/EEC, the In Vitro Diagnostic Medical Devices Directive – 98/79/EC and the Active Implantable Medical Devices Directive – 90/385/EEC), which make the crucial acts of "placing on the market" and "putting into service" subject to compliance with the regulatory requirements under these directives.
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.